TREM2 Agonist Therapy for Neurodegeneration
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonist Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">HL-85</td>
<td>H3 Biomedicine/Eisai</td>
</tr>
<tr>
<td class="label">H3B-10252</td>
<td>H3 Biomedicine</td>
</tr>
</table>
TREM2 agonist therapy represents a breakthrough immunomodulatory approach targeting the [Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) pathway to enhance microglial function across multiple neurodegenerative diseases. TREM2 is a cell surface receptor primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system and plays a critical role in modulating the brain's innate immune response. [@trem2020]
Loss-of-function variants in the TREM2 gene (such as R47H, R62H, R47H) significantly increase risk for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia), making TREM2 activation a promising therapeutic strategy across these conditions. [@trem2022]
Mechanism of Action
TREM2 is a cell surface receptor on microglia that recognizes multiple ligands including [amyloid-beta](/proteins/amyloid-beta) plaques, lipid particles, [apolipoprotein E](/proteins/apoe) (apoE), and cellular debris. Upon ligand binding, TREM2 signals through the adaptor protein TYROBP (DAP12) to activate downstream pathways including PI3K/Akt, MAPK/ERK, and SYK kinase. This signaling drives critical microglial functions: [@trem2021]
- Phagocytosis: TREM2 activation enhances microglial clearance of pathological protein aggregates and cellular debris
- Metabolic reprogramming: TREM2 signaling supports the inflammatory metabolic state of disease-associated microglia (DAM)
- Survival signaling: TREM2 provides pro-survival signals that prevent microglial [apoptosis](/entities/apoptosis)
- Clustering: TREM2 promotes microglial clustering around pathological lesions, forming a protective barrier
The TREM2 agonist approach aims to bypass the need for functional TREM2 variants by delivering exogenous activation signals that restore or enhance microglial function. This is particularly important for patients with TREM2 risk variants who have reduced endogenous TREM2 signaling.
Clinical Candidates
AL002 (Alector/AbbVie)
AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the most advanced TREM2-targeting antibody in clinical development.
- Mechanism: Agonist antibody binding to extracellular domain of TREM2
- Company: Alector (developed with AbbVie)
- Phase: Phase 2 (INVOKE-2 trial)
- Indications: [Alzheimer's disease](/diseases/alzheimers-disease)
Clinical Trial Status
Phase 1 Results
The Phase 1 study demonstrated:
- Dose-dependent engagement of TREM2
- Acceptable safety profile in healthy volunteers and AD patients
- Increased CSF sTREM2 levels indicating target engagement
- No serious treatment-related adverse events [@phase2024]
HL-85 (H3 Biomedicine/Eisai)
HL-85 (also known as H3B-10252) is a TREM2-targeting monoclonal antibody being developed by H3 Biomedicine (a subsidiary of Eisai) for neurodegenerative diseases.
- Mechanism: Agonist antibody targeting TREM2 to enhance microglial function
- Company: H3 Biomedicine (Eisai)
- Preclinical/Phase 1: Early-stage development
- Indications: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease)
Development Status
HL-85 represents Eisai's entry into the TREM2 agonist space, leveraging their experience with [lecanemab](/entities/lecanemab) and other Alzheimer's therapeutics. The program aims to develop a TREM2 agonist with optimal brain penetration and dosing. [@eisai2024]
Other Pipeline Agents
Evidence by Disease
Alzheimer's Disease (AD)
TREM2 agonists have the strongest clinical evidence in Alzheimer's disease, where microglial dysfunction plays a central role in disease progression.
Genetic Rationale
- TREM2 R47H variant: 3-4x increased AD risk; impairs ligand binding
- TREM2 R62H variant: ~2x increased AD risk; partial loss of function
- TREM2 loss-of-function: Reduces microglial phagocytosis of amyloid
Clinical Evidence
- AL002 Phase 1 showed dose-dependent TREM2 engagement
- CSF sTREM2 elevation correlates with treatment response
- Amyloid plaque clearance observed in preclinical models
- INVOKE-2 trial evaluating clinical efficacy endpoints [@invoke]
Biomarker Endpoints
- Amyloid PET (Centiloid reduction)
- CSF biomarkers (p-tau181, total tau, Aβ42/40)
- CSF sTREM2 (target engagement marker)
- MRI volumetric measures
Parkinson's Disease (PD)
TREM2 is implicated in [Parkinson's disease](/diseases/parkinsons-disease) through its role in clearing [alpha-synuclein](/proteins/alpha-synuclein) aggregates and regulating neuroinflammation.
Genetic Rationale
- TREM2 variants associated with PD risk
- Reduced TREM2 function may impair alpha-synuclein clearance
- Neuroinflammation drives PD progression
Clinical Development
- HL-85 being evaluated for PD indication
- Preclinical data supports alpha-synuclein clearance
- Phase 1/2 trials anticipated
Corticobasal Syndrome (CBS)
[Corticobasal syndrome](/diseases/corticobasal-syndrome) involves tau pathology and benefits from microglial modulation.
Rationale
- TREM2 activation may enhance tau clearance
- Neuroinflammation contributes to CBS progression
- Microglial clustering around tau lesions
Clinical Status
- No current TREM2 trials in CBS
- Potential indication for future development
Progressive Supranuclear Palsy (PSP)
[Progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) is a tauopathy that may benefit from TREM2 agonism.
Rationale
- Tau pathology triggers microglial activation
- TREM2 may help clear tau aggregates
- Neuroinflammation drives disease progression
Clinical Status
- No current TREM2 trials in PSP
- Scientific rationale supports investigation
Amyotrophic Lateral Sclerosis (ALS)
[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) involves motor neuron degeneration with microglial involvement.
Genetic Rationale
- TREM2 variants associated with ALS risk
- Microglial dysfunction contributes to motor neuron damage
- Enhanced microglial function may slow progression
Clinical Status
- No current TREM2 trials in ALS
- Preclinical models show promise
Frontotemporal Dementia (FTD)
[Frontotemporal dementia](/diseases/frontotemporal-dementia) involves protein aggregates and neuroinflammation.
Genetic Rationale
- TREM2 variants linked to FTD risk
- Microglial activation in FTD pathology
- Protein aggregate clearance role
Clinical Status
- No current TREM2 trials in FTD
- Potential future indication
Huntington's Disease
[Huntington's disease](/diseases/huntingtons) involves mutant huntingtin protein aggregation and microglial activation.
Rationale
- TREM2 may enhance mutant huntingtin clearance
- Neuroinflammation contributes to progression
- Microglial modulation potential therapeutic approach
Clinical Status
- No current TREM2 trials in HD
- Preclinical rationale exists
Biomarkers and Patient Selection
CSF sTREM2
Soluble TREM2 (sTREM2) in cerebrospinal fluid reflects TREM2 shedding and microglial activation.
- Baseline sTREM2: May predict response to TREM2 agonists
- Dynamic changes: Treatment-induced sTREM2 increase indicates target engagement
- Correlation: Higher sTREM2 in early disease stages
Genetic Stratification
Patients with TREM2 risk variants may particularly benefit from TREM2 agonism:
- R47H carriers: ~3-4x increased AD risk; reduced ligand binding
- R62H carriers: Intermediate risk; partial loss of function
- R47H homozygotes: Very high risk; may benefit most from therapy
Proteinopathy Status
TREM2 agonists require the presence of pathological protein aggregates as ligands:
- Amyloid-positive: Required for AD trials
- Alpha-synucleinpositive: Target for PD trials
- Tau-positive: Important for all tauopathies
Safety Considerations
Expected ARIA
Similar to other antibody therapies targeting immune pathways:
- ARIA-E: Amyloid-related imaging abnormalities - edema; monitoring required
- ARIA-H: Microhemorrhages; less common than with amyloid antibodies
- Injection site reactions (for subcutaneous formulations)
- Flu-like symptoms
- Potential for enhanced infection risk
Monitoring Requirements
- MRI at baseline and during treatment
- Regular neurological assessments
- CSF sampling for biomarker monitoring
Future Directions
Combination Approaches
TREM2 agonists may be combined with:
- [Amyloid-targeting antibodies](/therapeutics/amyloid-immunotherapies) (lecanemab, donanemab)
- [Tau-targeting therapies](/therapeutics/tau-immunotherapies-neurodegeneration)
- [Anti-inflammatory agents](/therapeutics/neuroinflammation-modulation-therapies)
Next-Generation Agents
- Small molecule TREM2 agonists
- Gene therapy approaches
- Engineered bispecific antibodies
Cross-Linking
- TREM2 Gene
- [Microglia](/cell-types/microglia)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Amyloid Immunotherapies
- Tau Immunotherapies
- Neuroinflammation Modulation
- Microglial Modulation Therapy
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- Progressive Supranuclear Palsy
- Corticobasal Syndrome
- [Huntington's Disease](/diseases/huntingtons)
References
[Unknown, TREM2: A Microglial Receptor for Amyloid Clearance (Cell, 2020) (2020)](https://doi.org/10.1016/j.cell.2020.09.020)
[Unknown, TREM2 Variants and Neurodegeneration Risk (Nature Reviews Neurology, 2022) (2022)](https://doi.org/10.1038/s41582-022-00645-4)
[Unknown, TREM2 Signaling in Microglial Function (Nature Neuroscience, 2021) (2021)](https://doi.org/10.1038/s41593-021-00856-w)
Unknown, AL002 Phase 1 Results (Alector Corporate Presentation, 2024) (2024)
Unknown, Eisai TREM2 Program (Eisai Pipeline, 2024) (2024)
Unknown, INVOKE-2 Trial Design (ClinicalTrials.gov NCT05155020) (n.d.)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) 🔄
- [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) 🔄
- [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄